Intellia Therapeutics (NTLA) Return on Sales: 2015-2025
Historic Return on Sales for Intellia Therapeutics (NTLA) over the last 10 years, with Sep 2025 value amounting to -7.74%.
- Intellia Therapeutics' Return on Sales rose 359.00% to -7.74% in Q3 2025 from the same period last year, while for Sep 2025 it was -7.74%, marking a year-over-year increase of 359.00%. This contributed to the annual value of -8.40% for FY2024, which is 443.00% up from last year.
- Per Intellia Therapeutics' latest filing, its Return on Sales stood at -7.74% for Q3 2025, which was up 13.53% from -8.95% recorded in Q2 2025.
- Intellia Therapeutics' 5-year Return on Sales high stood at -2.88% for Q1 2021, and its period low was -12.83% during Q4 2023.
- For the 3-year period, Intellia Therapeutics' Return on Sales averaged around -9.42%, with its median value being -8.87% (2024).
- In the last 5 years, Intellia Therapeutics' Return on Sales plummeted by 929bps in 2021 and then soared by 443bps in 2024.
- Quarterly analysis of 5 years shows Intellia Therapeutics' Return on Sales stood at -10.19% in 2021, then surged by 157bps to -8.63% in 2022, then crashed by 420bps to -12.83% in 2023, then spiked by 443bps to -8.40% in 2024, then spiked by 359bps to -7.74% in 2025.
- Its Return on Sales stands at -7.74% for Q3 2025, versus -8.95% for Q2 2025 and -10.91% for Q1 2025.